Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia-Reference-Cited by-同舟云学术

Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia

Published:2016-11-29 Issue:12 Volume:31 Page:1927-1932
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Merlo Gregory¹,Graves Nicholas¹,Brain David¹,Connelly Luke B²

Affiliation:

1. Queensland University of Technology (QUT); Australian Centre for Health Services Innovation (AusHSI) and the Centre of Research Excellence in Reducing Healthcare Associated Infections; Brisbane Queensland Australia

2. The University of Queensland; Faculty of Health and Behavioural Sciences and Centre for the Business and Economics of Health; Brisbane Queensland Australia

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.13402/fullpdf

Reference40 articles.

1. Clostridium difficile colitis;Kelly;N. Engl. J. Med.,1994

2. Recurrent Clostridium difficile diarrhoea;Kyne;Gut,2001

3. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease;McFarland;Am. J. Gastroenterol.,2002

4. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease;McFarland;JAMA,1994

5. Measuring the incidence of Clostridium difficile-associated diarhoea in a group of Western Australian hospitals;Van Gessel;Healthc. Infect.,2008

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clustering Disease of Clostridioides Difficile Infection: Implication for the Management in Internal Medicine;Microbiology Research;2023-09-15

2. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA;Advances in Therapy;2023-04-24

3. Fecal Transplant: The Benefits and Harms of Fecal Microbiota Transplantation;Clinical Understanding of the Human Gut Microbiome;2023

4. The demand–supply gap for faecal microbiota transplantation in Australia and New Zealand: a survey of infectious diseases physicians;Internal Medicine Journal;2022-07

5. Defining the decision problem: a scoping review of economic evaluations for Clostridioides difficile interventions;Journal of Hospital Infection;2022-03